ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Targeting Adipose Tissue Function Protects Against Heart Failure with Preserved Ejection Fraction.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Adipose Tissue Function Protects Against Heart Failure with Preserved Ejection Fraction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
This study seeks to develop a better understanding of how the targeting of adipose tissue (AT) can mediate outcomes in cardiac function. Obesity is highly prevalent among individuals with heart failure with preserved ejection fraction (HFpEF). While thermogenic AT helps counteract obesity-related conditions, its impact on heart function in obesity-related HFpEF is unclear. Using a "two-hit" HFpEF model, the study evaluates the impact of thermogenic AT on cardiac function through pharmacological, surgical, and genetic interventions. Activation of thermogenic AT via the β3-adrenergic receptor agonist CL-316,243 (CL) improves cardiac function, protects against HFpEF-induced remodeling, and enhances energy expenditure. Similarly, transplantation of AT from CL-treated mice into wild-type recipients confers cardioprotection. In contrast, genetic suppression of thermogenesis (Adipoq-Cre; Prdm16
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.